AMENDMENTS TO THE CLAIMS

The list below will replace all prior versions, and listings, of claims in the application.

LISTING OF CLAIMS

Claims 1-204 (Canceled)

Claim 205. (Previously Presented) A method for suppressing an allergic reaction in response to an antigen in a mammal susceptible to an allergic reaction to said antigen which stimulates production of allergy-associated IgE antibodies in the mammal, comprising parenterally co-administering to the mammal

(a) an effective amount of an immunostimulatory nucleic acid in a plasmid, said immunostimulatory nucleic acid comprising 5'CG3', wherein C is unmethylated, and

(b) an effective amount of the antigen provided as the antigen *per se* or as a polynucleotide encoding the antigen.

Claim 206. (New) The method of claim 205, wherein the antigen is provided as the antigen *per se*.

Claim 207 (New). The method of claim 205, wherein the antigen is provided as a polynucleotide encoding the antigen.

Claim 208 (New). The method of claim 207, wherein the polynucleotide encoding the antigen and the immunostimulatory nucleic acid are part of the same plasmid.

Claim 209 (New). The method of claim 208, wherein the plasmid is pREP7.

Claim 210. (New) The method of claim 205, wherein the immunostimulatory nucleic acid comprises AACGTT (SEQ ID NO: 1), GACGTC (SEQ ID NO: 4), AGCGCT (SEQ ID NO: 5), ATCGAT (SEQ ID NO: 6), CGATCG (SEQ ID NO: 7), CGTACG (SEQ ID NO: 8), CGCGCG (SEQ ID NO: 9); TCGCGA (SEQ ID NO: 10), GACGATCGTC (SEQ ID NO: 13), ACGATCGT (SEQ ID NO: 14), CGACGATCGTCG (SEQ ID NO: 15), CGACGACGATCGTCGTCG (SEQ ID NO: 16), CAACGTTG (SEQ ID NO: 17), ACAACGTTGT (SEQ ID NO: 18), AACAACGTTGTT (SEQ ID NO: 19), or CAACAACGTTGTTG (SEQ ID NO: 20).

Claim 211 (New). A method for suppressing an allergic reaction in response to an antigen in a mammal susceptible to an allergic reaction to said antigen which stimulates production of allergy-associated IgE antibodies in the mammal, comprising co-administering to the mammal (a) an effective amount of an immunostimulatory nucleic acid in a plasmid, said immunostimulatory nucleic acid comprising 5'CG3', wherein C is unmethylated, and (b) an effective amount of the antigen provided as the antigen *per se* or as a polynucleotide encoding the antigen.

Claim 212. (New) The method of claim 211, wherein the antigen is provided as the antigen *per se*.

Claim 213 (New). The method of claim 211, wherein the antigen is provided as a polynucleotide encoding the antigen.

Claim 214 (New). The method of claim 213, wherein the polynucleotide encoding the antigen and the immunostimulatory nucleic acid are part of the same plasmid.

Claim 215 (New). The method of claim 214, wherein the plasmid is pREP7.

Claim 216. (New) The method of claim 211, wherein the immunostimulatory nucleic acid comprises AACGTT (SEQ ID NO: 1), GACGTC (SEQ ID NO: 4), AGCGCT (SEQ ID NO: 5), ATCGAT (SEQ ID NO: 6), CGATCG (SEQ ID NO: 7), CGTACG (SEQ ID NO: 8), CGCGCG (SEQ ID NO: 9); TCGCGA (SEQ ID NO: 10), GACGATCGTC (SEQ ID NO: 13), ACGATCGT (SEQ ID NO: 14), CGACGATCGTCG (SEQ ID NO: 15), CGACGACGATCGTCGTCG (SEQ ID NO: 16), CAACGTTG (SEQ ID NO: 17), ACAACGTTGT (SEQ ID NO: 18), AACAACGTTGTT (SEQ ID NO: 19), or CAACAACGTTGTTG (SEQ ID NO: 20).

Claim 217. (New) A method for suppressing an allergic reaction in response to an antigen in a mammal susceptible to an allergic reaction to said antigen which stimulates production of allergy-associated IgE antibodies in the mammal, comprising parenterally co-administering to the mammal

(a) an effective amount of an immunostimulatory nucleic acid, said immunostimulatory nucleic acid comprising 5'CG3', wherein C is unmethylated, and

(b) an effective amount of the antigen provided as the antigen *per se* or as a polynucleotide encoding the antigen.

Claim 218. (New) The method of claim 217, wherein the antigen is provided as the antigen *per se*.

Claim 219 (New). The method of claim 217, wherein the antigen is provided as a polynucleotide encoding the antigen.

Claim 220. (New) The method of claim 217, wherein the immunostimulatory nucleic acid comprises AACGTT (SEQ ID NO: 1), GACGTC (SEQ ID NO: 4), AGCGCT (SEQ ID NO: 5), ATCGAT (SEQ ID NO: 6), CGATCG (SEQ ID NO: 7), CGTACG (SEQ ID NO: 8), CGCGCG (SEQ ID NO: 9); TCGCGA (SEQ ID NO: 10), GACGATCGTC (SEQ ID NO: 13), ACGATCGT (SEQ ID NO: 14), CGACGATCGTCG (SEQ ID NO: 15), CGACGACGATCGTCGTCG (SEQ ID NO: 16), CAACGTTG (SEQ ID NO: 17),

ACAACGTTGT (SEQ ID NO: 18), AACAACGTTGTT (SEQ ID NO: 19), or CAACAACGTTGTTG (SEQ ID NO: 20).

Claim 221 (New). A method for suppressing an allergic reaction in response to an antigen in a mammal susceptible to an allergic reaction to said antigen which stimulates production of allergy-associated IgE antibodies in the mammal, comprising co-administering to the mammal (a) an effective amount of an immunostimulatory nucleic acid, said immunostimulatory nucleic acid comprising 5'CG3', wherein C is unmethylated, and
(b) an effective amount of the antigen provided as the antigen *per se* or as a polynucleotide encoding the antigen.

Claim 222. (New) The method of claim 221, wherein the antigen is provided as the antigen *per se*.

Claim 223 (New). The method of claim 221, wherein the antigen is provided as a polynucleotide encoding the antigen.

Claim 224. (New) The method of claim 221, wherein the immunostimulatory nucleic acid comprises AACGTT (SEQ ID NO: 1), GACGTC (SEQ ID NO: 4), AGCGCT (SEQ ID NO: 5), ATCGAT (SEQ ID NO: 6), CGATCG (SEQ ID NO: 7), CGTACG (SEQ ID NO: 8), CGCGCG (SEQ ID NO: 9); TCGCGA (SEQ ID NO: 10), GACGATCGTC

(SEQ ID NO: 13), ACGATCGT (SEQ ID NO: 14), CGACGATCGTCG (SEQ ID NO: 15), CGACGACGATCGTCGTCG (SEQ ID NO: 16), CAACGTTG (SEQ ID NO: 17), ACAACGTTGT (SEQ ID NO: 18), AACAACGTTGTT (SEQ ID NO: 19), or CAACAACGTTGTTG (SEQ ID NO: 20).